Elisabeth Leiderman
Director/Board Member presso BLUEBIRD BIO, INC.
Patrimonio netto: 28 488 $ in data 31/03/2024
Profilo
Elisabeth Leiderman is an Independent Director at bluebird bio, Inc. and a Non-Executive Director at Autolus Therapeutics Plc.
She previously worked as an Executive Director at Nomura Securities, Inc., VP-Business & Corporate Development at Fortress Biotech, Inc., Chief Business Officer at Complexa, Inc., Chief Financial & Accounting Officer at Decibel Therapeutics, Inc., and Chief Financial & Business Officer at Atsena Therapeutics, Inc. Dr. Leiderman holds an undergraduate degree from the University of Pennsylvania, an MBA from The Wharton School of the University of Pennsylvania, and a doctorate from Sackler School of Medicine.
Partecipazioni note in società pubbliche
| Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
|---|---|---|---|---|
BLUEBIRD BIO, INC.
0.01% | 16/06/2023 | 22 256 ( 0.01% ) | 28 488 $ | 31/03/2024 |
Posizioni attive di Elisabeth Leiderman
| Società | Posizione | Inizio |
|---|---|---|
| BLUEBIRD BIO, INC. | Director/Board Member | 15/10/2021 |
| AUTOLUS THERAPEUTICS PLC | Director/Board Member | 20/12/2023 |
Precedenti posizioni note di Elisabeth Leiderman
| Società | Posizione | Fine |
|---|---|---|
Atsena Therapeutics, Inc.
 Atsena Therapeutics, Inc. BiotechnologyHealth Technology Atsena Therapeutics, Inc. engages in biotechnology business. The company is headquartered in Durham, NC. | Director of Finance/CFO | 01/11/2023 |
| DECIBEL THERAPEUTICS, INC. | Director of Finance/CFO | 07/10/2022 |
Complexa, Inc.
 Complexa, Inc. Pharmaceuticals: MajorHealth Technology Complexa, Inc. operates as a biopharmaceutical company which engages on discovering and developing therapies for the treatment of severe and life-threatening fibrosis and inflammatory diseases. The firm focuses on two therapeutic areas: focal segmental glomerulosclerosis (FSGS) and pulmonary arterial hypertension (PAH), two rare diseases that can compromise the normal function of the kidney and the heart. The company was founded by Bruce A. Freeman, Raymond A. Miller, and Margaret M. Tarpey in 2008 and is headquartered in Berwyn, PA. | Corporate Officer/Principal | 01/08/2020 |
| Nomura Securities, Inc. | Director/Board Member | 01/07/2016 |
| FORTRESS BIOTECH, INC. | Corporate Officer/Principal | 01/01/2016 |
Formazione di Elisabeth Leiderman
| University of Pennsylvania | Undergraduate Degree |
| The Wharton School of the University of Pennsylvania | Masters Business Admin |
| Sackler School of Medicine | Doctorate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 4 |
|---|---|
| FORTRESS BIOTECH, INC. | Health Technology |
| BLUEBIRD BIO, INC. | Health Technology |
| DECIBEL THERAPEUTICS, INC. | Health Technology |
| AUTOLUS THERAPEUTICS PLC | Health Technology |
| Aziende private | 3 |
|---|---|
Complexa, Inc.
Complexa, Inc. Pharmaceuticals: MajorHealth Technology Complexa, Inc. operates as a biopharmaceutical company which engages on discovering and developing therapies for the treatment of severe and life-threatening fibrosis and inflammatory diseases. The firm focuses on two therapeutic areas: focal segmental glomerulosclerosis (FSGS) and pulmonary arterial hypertension (PAH), two rare diseases that can compromise the normal function of the kidney and the heart. The company was founded by Bruce A. Freeman, Raymond A. Miller, and Margaret M. Tarpey in 2008 and is headquartered in Berwyn, PA. | Health Technology |
Atsena Therapeutics, Inc.
Atsena Therapeutics, Inc. BiotechnologyHealth Technology Atsena Therapeutics, Inc. engages in biotechnology business. The company is headquartered in Durham, NC. | Health Technology |
| Nomura Securities, Inc. |
- Borsa valori
- Insiders
- Elisabeth Leiderman
